The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease

The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease
J Neuroinflammation. 2021 Apr 6;18(1):88. doi: 10.1186/s12974-021-02132-z.ABSTRACTBACKGROUND: It is suggested that neuroinflammation, in which activated microglial cells play a relevant role, contributes to the development of Parkinson's disease (PD). Consequently, the modulation of microglial activation is a potential therapeutic target to be taken into account to act against the dopaminergic neurodegeneration occurring in this neurological disorder. Several soluble and membrane-associated ... read more
Source: PubMedPublished on 2021-04-07By Neus Rabaneda-Lombarte